Article Contents ::
Details About Generic Salt :: Lovastatin
Main Medicine Class:: Cardiovascular System Sub Medicine Class :: Fluid , Electrolyte Preparations
| 4F. ANTI-HYPERLIPIDEMICS in 4. CARDIOVASCULAR SYSTEM |
| LOVASTATIN |
| HMG-COA REDUCTASE INHIBITOR | ANTI-HYPERLIPIDEMIC |
| PK: M: Liver E: Feces |
|
Indications & Dose: HYPERLIPIDEMIA PO Adult Initially 20mg then adjust at 4 wk intervals, max 80mg/day Child 10-17 yr: IR tablet 10mg/day (for LDL reduction <20%) or 20mg/day (for LDL reduction >20%), adjust at 4 wk intervals, max 40mg/day |
| Contra: Hypersensitivity, active liver disease, unexplained persistent elevations of serum transaminases
Precautions: Cerebral arteriosclerosis, CVD, renal impairment, severe acute infect, severe hypotension/HTN, uncontrolled seizures, myopathy, visual disturbances, major surgery, trauma, alcoholism, severe metabolic/endocrine/electrolyte problems, patients at risk of rhabdomyolysis, reduce initial dose (by 50%) in patients recieving ciclosporin/danazol ADR: Serious: blurred vision, Hepatotoxicity, rhabdomyolysis, hypersensitivity reactions, Others: Headache, dizziness, asthenia, eye irritation, nausea, vomiting, constipation, diarrhea, abdominal pain/cramps, dyspepsia, flatulence, myalgia, cramps, pruritus, rash, photosensitivity DDI: Serious Diltiazem/Ciclosporin/Itraconazole causes marked rise in drug serum levels, Nefazodone causes muscle toxicity & rhabdomyolysis, Danazol causes severe rhabdomyolysis & myoglobinuria, Gemfibrozil/Delavirdine increases drug level, Macrolides increases drug levels (myopathy & rhabdomyolysis) Diet: With food Monitor: LFTs, TC profile, baseline CPK |
